EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

CFTR correctors potentiate gating mutants causing cystic fibrosis

Solène Castanier, Ahmad Elbahnsi, Benoit Chevalier, Lynda Berri, Madara Dias Wickramanayaka, Jean-Paul Mornon, Aurélie Hatton, Isabelle Sermet-Gaudelus, Aleksander Edelman, Isabelle Callebaut, Alexandre Hinzpeter

Journal of Cystic Fibrosis · 2026

DOI: 10.1016/j.jcf.2025.11.008 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cystic Fibrosis, 2026. Verfasst von Solène Castanier und 10 weiteren Autor:innen. Beteiligte Einrichtung: Université Paris Cité, INSERM U1151, CNRS UMR8253, Institut Necker Enfants Malades F-75015 Paris, France. Hauptthemen laut MEDLINE: Cystic Fibrosis Transmembrane Conductance Regulator, Cystic Fibrosis, Propylamines, Pyridines. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Association Vaincre la Mucoviscidose.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The Cystic Fibrosis Transmembrane conductance Regulator (CFTR) modulator VX-445 (Elexacaftor) used to treat cystic fibrosis presents both corrector and potentiator activities. This drug binds to a pocket within the CFTR membrane-spanning domain (MSD) assembly, in contact with the lasso motif. We have previously shown that the corrector activity of VX-445 is modulated by mutations within MSD1 and the nucleotide binding domain NBD1. Here, we evaluate if mutations affecting VX-445's corrector activity also affect its potentiator activity. Responses to increasing concentrations of VX-445 were measured using the halide sensitive fluorescent assay after transfection of CFTR mutants in HEK293 cells. Results show that VX-445 potentiated gating mutants causing cystic fibrosis located in the NBDs (NBD1 G551D and NBD2 G1349D) and in the IntraCellular Loops (ICL1 G178R and ICL3 G970R). Mutations within the VX-445 binding site inhibited potentiation of G551D, contrary to some mutations located outside this site that affected its corrector activity, two of which (M212A and F224A) were found to induce CFTR gain-of-function. Potentiation of G551D was also observed with correctors VX-809 and VX-121. In conclusion, CFTR modulator VX-445 can promote channel activity of gating mutants, an effect which is dependent on the integrity of its binding site. Potentiation could also be observed with correctors VX-809 and VX-121, indicating that more generally, CFTR correctors can promote channel activity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic Fibrosis Transmembrane Conductance RegulatorCystic FibrosisPropylaminesPyridinesHumansMutationBenzodioxolesIon Channel GatingAminopyridinesChloride Channel AgonistsAminophenolsHEK293 CellsPyrazolesPyrrolidines

Stichwörter der Autor:innen

CFTR structure functionCorrectorsCystic fibrosisGain of function mutationpotentiation

Substanzen

Cystic Fibrosis Transmembrane Conductance RegulatorelexacaftorBenzodioxolesCFTR protein, humanAminopyridinesChloride Channel AgonistsAminophenolsPropylaminesPyridinesPyrazoles

Autor:innen und Institutionen

  • Université Paris Cité, INSERM U1151, CNRS UMR8253, Institut Necker Enfants Malades F-75015 Paris, France.
  • Université Paris Cité, CNRS UMR 8038 CiTCoM, Inserm U1268 MCTR, Paris, France.
  • Sorbonne Université, Muséum National d'Histoire Naturelle, UMR CNRS 7590, Institut de Minéralogie, de Physique des Matériaux et de Cosmochimie IMPMC, 75005 Paris, France.
  • Université Paris Cité, INSERM U1151, CNRS UMR8253, Institut Necker Enfants Malades F-75015 Paris, France; Centre Maladies rares Mucoviscidose et maladies apparentées, Hôpital Necker Enfants Malades, Assistance Publique…
  • Sorbonne Université, Muséum National d'Histoire Naturelle, UMR CNRS 7590, Institut de Minéralogie, de Physique des Matériaux et de Cosmochimie IMPMC, 75005 Paris, France. Electronic address: isabelle.callebaut@sorbonne-…
  • Université Paris Cité, INSERM U1151, CNRS UMR8253, Institut Necker Enfants Malades F-75015 Paris, France. Electronic address: alexandre.hinzpeter@inserm.fr.

Förderung

  • Association Vaincre la Mucoviscidose

Zitieren

APA

Castanier, S., Elbahnsi, A., Chevalier, B., Berri, L., Dias Wickramanayaka, M., Mornon, J. P., Hatton, A., Sermet-Gaudelus, I., Edelman, A., Callebaut, I., & Hinzpeter, A. (2026). CFTR correctors potentiate gating mutants causing cystic fibrosis. Journal of Cystic Fibrosis. https://doi.org/10.1016/j.jcf.2025.11.008

Vancouver

Castanier S, Elbahnsi A, Chevalier B, Berri L, Dias Wickramanayaka M, Mornon JP, et al. CFTR correctors potentiate gating mutants causing cystic fibrosis. Journal of Cystic Fibrosis. 2026. doi:10.1016/j.jcf.2025.11.008

BibTeX
@article{Castanier2026,
  author = {Castanier, Solène and Elbahnsi, Ahmad and Chevalier, Benoit and Berri, Lynda and Dias Wickramanayaka, Madara and Mornon, Jean-Paul and Hatton, Aurélie and Sermet-Gaudelus, Isabelle and Edelman, Aleksander and Callebaut, Isabelle and Hinzpeter, Alexandre},
  title = {CFTR correctors potentiate gating mutants causing cystic fibrosis},
  journal = {Journal of Cystic Fibrosis},
  year = {2026},
  doi = {10.1016/j.jcf.2025.11.008}
}
Kostenlos starten →